stockportfolio.pro
CYTK vs HALO: Which Stock Is the Better Buy?
Cytokinetics, Incorporated and Halozyme Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CYTK vs HALO, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Cytokinetics, Incorporated (CYTK) | Halozyme Therapeutics, Inc. (HALO) | |
|---|---|---|
| Market cap | $9.1B | $8.4B |
| Revenue (latest FY) | $88.04M | $1.40B |
| Net income (latest FY) | $-784.96M | $316.89M |
| Revenue growth (5y CAGR) | 9.5% | 39.2% |
| Net margin | -891.6% | 22.7% |
| Return on equity | 119.0% | 649.2% |
| P/E ratio | — | 24.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 7 |
| Positive free cash flow | No | Yes |
See the full CYTK vs HALO breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CYTK's full financials → Open HALO's full financials →More comparisons
Frequently asked questions
Which is bigger, CYTK or HALO?
Cytokinetics, Incorporated is larger by market capitalization — $9.1B versus $8.4B.
Which grows faster, CYTK or HALO?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus 9.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.